Abstract 1389
Background
Anti-VEGF & anti-DLL4 have both demonstrated single agent activity in ovarian cancer. Navicixizumab is an anti-DLL4/VEGF IgG2 bispecific monoclonal antibody that had a response rate of 25% (3/12) in heavily pretreated ovarian cancer pts who were treated in an earlier single agent phase Ia trial.
Methods
This is an ongoing Phase 1b study of paclitaxel & navicixizumab in platinum resistant ovarian cancer pts who have failed > 2 prior therapies &/or bevacizumab. Paclitaxel 80 mg/m2 is given on Days 1, 8 and 15 & navicixizumab is given on Days 1 & 15 of every 28 day cycle. This study was designed as a dose escalation trial testing navicixizumab doses of 3 or 4 mg/kg followed by an expansion cohort to enroll a total of 30 patients. The expansion cohort was undertaken with 3 mg/kg of navicixizumab as higher doses did not show increased activity, but did result in more pronounced chronic toxicity in the Phase 1a study. A standardized treatment algorithm for hypertension is being employed.
Results
Eighteen pts were treated; 5 are still ongoing. The median number of prior therapies was 4 (range 2-8), all 18 pts had received prior paclitaxel & 13 had received bevacizumab. Eight pts (44%) had a PR, 6 (33%) had SD, 2 (11%) had PD & 2 (11%) were NE. The clinical benefit rate was 78%. Ten of 14 (71%) pts with an elevated CA-125 had a GCIG-defined response. The related AEs (all grades) that occurred in > 15% of the pts were: hypertension (67%), fatigue (44%), diarrhea (44%), headache (22%), neutropenia (17%), GERD (17%) & decrease appetite (17%). Other related AEs of significance were an infusion reaction (6%), Gr2 pulmonary hypertension (6%), Gr 4 thrombocytopenia (6%) & Gr4 GI perforation (6%). Anti-drug antibody occurred in 3 of 16 pts who have been evaluated; drug exposure was impacted in 1 pt.
Conclusions
The efficacy data in these heavily pre-treated platinum resistant ovarian cancer pts are encouraging & enrollment is ongoing. The safety profile appears to be manageable with hypertension being the most common adverse event related to navicixizumab.
Clinical trial identification
NCT03030287 January 25, 2017.
Legal entity responsible for the study
OncoMed Pharmaceuticals.
Funding
OncoMed Pharmaceuticals.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2300 - AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)
Presenter: Claudia Cardone
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2834 - Multimodal detection of homologous recombination repair gene mutations (HRRm) in a Phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)
Presenter: Thomas Carr
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3596 - Identification of a highly suppressive Treg subset associated to immunotherapy response
Presenter: Emilio Giunta
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3705 - A Novel Framework for Evaluating Biomarker Response Relationships in Immuno-oncology (IO)
Presenter: Jeffrey Evelhoch
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5332 - Comparison of OncoBEAM and NGS methods to detect plasma EGFR T790M mutations at progression of NSCLC
Presenter: Jessica Garcia
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5700 - Differential expression of PD-L1 and immune biomarkers by age: Decreased expression in pediatric/AYA patients with advanced cancer
Presenter: Omid Hamid
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
966 - Potential resistance mechanisms revealed primary resistance to crizotinib in ROS1+ non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Quxia Zhang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2171 - Prevalence of CLDN18.2, HER2, and PD-L1 in Gastric Cancer Samples
Presenter: Diarmuid Moran
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2318 - Epigenetic markers in circulating cell-free DNA for detection of early stage colorectal cancer
Presenter: Yanqun Liu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3625 - Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292
Presenter: Benjamin Besse
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract